 compar vitro activ new quinolon fleroxacin respiratori pathogen patient cystic fibrosi fleroxacin fluoroquinolon isol sputum patient cystic fibrosi isol rough mucoid pseudomona aeruginosa pseudomona cepacia staphylococcu aureu haemophilu influenza escherichia coli isol broth microdilut method influenc variou ph inoculum size biolog fluid serum sputum patient cystic fibrosi fleroxacin mic isol aeruginosa micrograms/ml cepacia micrograms/ml aureu microgram/ml influenza micrograms/ml coli micrograms/ml fleroxacin activ mucoid aeruginosa similar activ enoxacin ofloxacin ciprofloxacin activ norfloxacin enoxacin activ ciprofloxacin ofloxacin aureu fleroxacin inhibitori activ cepacia two- ciprofloxacin quinolon alter pH diluent inoculum size affect fleroxacin activ result avail pharmacokinet tissu distribut data support need clinic evalu fleroxacin pulmonari infect patient cystic fibrosi